Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib second-line treatment after checkpoint inhibitor therapy in advanced clear-cell renal cell carcinoma
NL-OMON52966Phase 2Active, not recruiting
- Sponsor
- Ipsen
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cabozantinib in renal cell carcinoma (RCC) (2 cohorts), sponsored by Ipsen. Primary endpoint: Objective response rate in Cohort A. Started Oct 2020; status: active, not recruiting.
02
Drugs
cabozantinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NL-OMON52966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52966.